Danaher Posts First Earnings Under New CEO; Emphasizes Need For Improved Execution, Innovation
Danaher Corp (NYSE: DHR) shares declined despite reporting upbeat third-quarter results, marking the first earnings call under new CEO Julie Sawyer Montgomery. Analysts from TD Cowen and Guggenheim Securities maintained Buy ratings but highlighted Sawyer Montgomery's emphasis on improved execution, innovation, and capital allocation discipline, as well as the impact of tariffs on revenue and the conservative 2027 outlook.
Danaher Analysts Raise Their Forecasts Following Better-Than-Expected Q3 Earnings
Danaher Corp. reported better-than-expected third-quarter earnings, with adjusted earnings of $2.11 per share and revenue up 8.5% year over year to $6.6 billion. Following these results, the company raised its fiscal 2026 adjusted earnings forecast, and several analysts increased their price targets for the stock. Despite the positive earnings, Danaher shares experienced a slight dip.
Zimmer Biomet Holdings, Inc. (ZBH) Stock forecasts
Argus analysts suggest that recent weakness in Zimmer Biomet Holdings, Inc. (ZBH) stock presents a buying opportunity. Based in Warsaw, Indiana, Zimmer Biomet is a leading orthopedic device maker and a component of the S&P 500. The company, formed from a 2015 merger, employs 17,000 people.
Zimmer Biomet Holdings, Inc. (ZBH) Stock forecasts
An Argus analyst report from October 22, 2026, suggests that recent weakness in Zimmer Biomet Holdings, Inc. (ZBH) stock offers a buying opportunity. Zimmer Biomet, based in Warsaw, Indiana, is the largest pure-play maker of orthopedic devices and is a component of the S&P 500. The report, authored by Senior Analyst David H. Toung, provides a summary and indicates a current price of $98.81.
US Stocks Starting with D: Complete List
This article provides a comprehensive list of 250 US-listed stocks available on INDmoney whose names begin with the letter "D", as of October 22, 2026. It highlights the top 10 stocks by market capitalization, led by Dell Technologies, and offers an alphabetical directory of all "D" stocks with details on accessing their individual pages for further information. The list is regularly updated to reflect new listings, renamings, or delistings.
UBS reiterates Danaher stock Buy rating on Q3 results and outlook
UBS has reiterated a Buy rating on Danaher Corp. (NYSE:DHR) stock with a $260.00 price target, following the company's Q3 results which met key expectations. Despite the stock trading near its 52-week high and delivering strong returns, InvestingPro data suggests it may be overvalued. Danaher reported Q3 2026 adjusted earnings and revenue above Wall Street's forecasts, though premarket trading saw a decline due to investor focus on the company’s outlook and ongoing respiratory revenue challenges.
Stifel raises Danaher stock price target to $260 on growth outlook
Stifel has increased its price target for Danaher Corp. (NYSE:DHR) shares to $260 from $220, maintaining a Buy rating, citing an expectation of more than 5% organic growth driven by Cytiva. Despite the raised target, the stock appears overvalued by InvestingPro analysis with a P/E ratio of 41.19. This adjustment follows Danaher's strong Q3 2026 earnings beat, though investor focus is shifting to future challenges related to respiratory revenue pressures.
HSBC Starts Public Service Enterprise Group Inc. (PEG) at Hold
HSBC analyst Meike Becker initiated coverage on Public Service Enterprise Group Inc. (NYSE: PEG) with a Hold rating and a $72.50 price target. The rating is based on projected RAB and EPS CAGRs below peer averages, with an adjusted TSR forecast of 10% for FY26-32e. PSEG, a regulated electricity and gas networks operator, faces political scrutiny in New Jersey, though potential upsides exist from nuclear contracting and state solar/storage targets.
ESCO Technologies Inc. (ESE) Stock Forecasts
Argus has lowered its target price for ESCO Technologies Inc. (ESE) to $272.00. The company, which sells engineered products and systems for various applications, currently trades at $232.95. This update is part of a quantitative report dated October 21, 2026.
DANAHER CORPORATION : JP MORGAN RAISES TARGET PRICE TO $270 FROM $250
J.P. Morgan has increased its target price for Danaher Corporation (DHR) shares to $270, up from the previous target of $250. This adjustment reflects an updated outlook from the investment bank regarding the company's valuation.
Illumina Jumps 5.4% Amid Sector-Wide Rally
Illumina's stock surged 5.4% Wednesday, closing at $282.31, as a broad sector-wide rally lifted diagnostics and research stocks. This jump reflects coordinated buying across the sector rather than company-specific news, with peers like Danaher and Medpace Holdings also seeing significant gains. Analyst sentiment remains positive, with recent target raises, indicating a constructive view on Illumina amidst reevaluated valuations in the healthcare landscape.
Thermo Fisher Scientific Tops Q3 2026 Profit Forecast With $6.68 EPS
Thermo Fisher Scientific Inc. reported strong Q3 2026 results, surpassing profit and revenue forecasts with an adjusted EPS of $6.68 and $12.14B in revenue. The company demonstrated solid operational execution, driven by 6.0% organic revenue growth and exceptional performance in its Laboratory Products and Biopharma Services segment. Despite the positive results, the stock saw a modest 1.2% increase, indicating investors may have already anticipated strong performance.
Danaher Corp. stock outperforms competitors on strong trading day
Shares of Danaher Corp. (DHR) rose 4.29% to $233.86 on Wednesday, outperforming competitors and the broader market. This gain ended a three-day losing streak for the company's stock. The S&P 500 Index and the Dow Jones Industrial Average also saw increases during the trading session.
Illumina Jumps 5.4% Amid Sector-Wide Rally
Illumina (ILMN) saw its stock surge by 5.4% as a broad rally lifted diagnostics and research stocks across the sector. This increase appears to be driven by coordinated buying and broader investor sentiment rather than company-specific news, with peers like Danaher (DHR) and Medpace Holdings (MEDP) also experiencing significant gains. Recent analyst activity has been positive, and investors are advised to monitor whether this sector-wide strength will be sustained.
Danaher’s Masimo acquisition offsets drops in respiratory diagnostic sales
Danaher reported its first full quarter results following the $9.9 billion acquisition of Masimo, which significantly boosted its diagnostics segment sales by 16.5%. Despite this, declines in respiratory testing, particularly for COVID-19, RSV, and influenza screeners, continued to temper the company's core revenues. Danaher met Wall Street's third-quarter expectations, but anticipates slower company-wide growth through the remainder of 2026 due to these respiratory testing headwinds.
Danaher Beats Profit Estimates, Raises Outlook as Customer Demand Improves
Danaher Corporation (NYSE: DHR) reported strong third-quarter results, surpassing analyst estimates for both earnings and revenue, driven by improving customer demand across its end markets. The company's core revenue growth, excluding respiratory testing, accelerated, leading to double-digit adjusted EPS growth. Danaher also raised its fiscal 2026 adjusted earnings forecast and provided a positive early outlook for fiscal 2027, anticipating continued core revenue growth.
[Danaher Q3 2026 Earnings Call] Danaher Beats Q3 Estimates With 5.5% Core Growth, Raises Full-Year EPS Guidance to $8.57-$8.62 as New CEO Pledges 'Unambiguous Share Gain'
Danaher reported strong Q3 2026 results, exceeding estimates with 5.5% core revenue growth excluding respiratory testing, and raising its full-year adjusted EPS guidance to $8.57-$8.62. New CEO Julie Sawyer Montgomery outlined priorities focused on commercial excellence, innovation, talent, and capital allocation, emphasizing "unambiguous share gain" as the company's key performance indicator. The company also provided an initial 2027 core growth framework of 4%-5% ex-respiratory, which was consistent with recent performance but slightly below some analyst expectations for acceleration.
Danaher Edges Past Q3 2026 Estimates, Posts $2.11 EPS, Revenue Up 8.5%
Danaher Corporation (NYSE: DHR) reported strong Q3 2026 results, with non-GAAP adjusted earnings of $2.11 per share, exceeding estimates by 8.8%, and revenue up 8.5% year-over-year to $6.55 billion. The company's performance was driven by robust demand in its life sciences and diagnostics franchises, with core revenue growth demonstrating underlying business health. Despite the solid beat, the stock traded largely unchanged, suggesting the market had already priced in strong results or is focusing on longer-term growth normalization.
Danaher Corporation 2026 Q3 - Results - Earnings Call Presentation (NYSE:DHR)
Danaher Corporation has published its slide deck in conjunction with its Q3 2026 earnings call. This presentation provides details related to the company's financial results for the third quarter. The article was written by SA Transcripts, a team responsible for developing and publishing earnings call transcripts on Seeking Alpha.
Danaher stock trades at EUR 195.85 before third-quarter results
Danaher stock is trading at EUR 195.85 ahead of its third-quarter results announcement, which is expected on October 21, 2026, with a consensus revenue forecast of USD 6.56 billion. The stock is down 2.37 percent from its previous Xetra close, even as analysts from TD Cowen, RBC Capital, and Barclays have recently raised their price targets and maintained positive ratings. The upcoming earnings report will be a key test for the stabilization of bioprocessing demand under CEO Julie Sawyer Montgomery.
Danaher stock drops after Q3 revenue miss (DHR:NYSE)
Danaher (DHR) shares dropped over 4% in premarket trading after the life sciences giant reported a Q3 2026 revenue miss, falling short of Street forecasts. This revenue miss coincides with a leadership transition within the Washington, DC-based company. Danaher reported $6.55 billion in revenue for the quarter.
Danaher Reports Q3 2026 Earnings Results
Danaher Corporation announced third-quarter results that exceeded analyst expectations, reporting adjusted earnings of $2.11 per share on revenue of $6.55 billion. The life sciences and diagnostics company saw an 8.5% increase in revenue year-over-year, driven by sustained demand across its diverse portfolio and strong core revenue growth excluding respiratory products. Management also provided full-year 2026 adjusted EPS guidance, with shares trading higher after the announcement.
DANAHER ($DHR) Releases Q3 2026 Earnings
Danaher ($DHR) reported its Q3 2026 earnings, with earnings per share beating estimates at $2.11 but revenue falling short at $6.554 billion. Insider trading activity for DHR shows primarily sales over the past six months, while institutional investors have both added and decreased their positions. The company has also seen significant government contracts and congressional stock trading activity.
Danaher shares rise in premarket trade as Q3 earnings beat estimates
Danaher Corporation (NYSE:DHR) reported better-than-expected third-quarter earnings and revenue, leading to a rise in its shares during premarket trading. The company exceeded analyst expectations with adjusted earnings of $2.11 per share and revenue of $6.6 billion. Danaher also raised its full-year 2026 adjusted diluted earnings per share guidance.
Danaher Corporation (DHR) Beats in Q3, Raises FY26 EPS Guidance
Danaher Corporation (DHR) reported stronger-than-expected Q3 results, with revenue, earnings, and cash flow all beating estimates. Following this performance, the company raised its adjusted diluted EPS guidance for fiscal year 2026 to $8.57–$8.62, an increase from its previous range of $8.45–$8.60. The positive revision signals improved profitability and continued underlying demand, despite some respiratory-related headwinds expected in Q4.
The Cooper Companies, Inc. (COO) stock price, news, quote and history
This article provides a comprehensive overview of The Cooper Companies, Inc. (COO) stock performance, including its current price, recent news headlines, and historical data. It also details the company's trailing total returns compared to the S&P 500 benchmark across different timeframes. The news section highlights various recent developments concerning the company, such as earnings reports, strategic reviews, and analyst opinions.
Danaher Corp. stock pre-market at EUR 197.68: laboratory tools group
Danaher Corp., a company specializing in biotechnology, diagnostics, and life sciences, saw its stock trading pre-market at EUR 197.68 at Lang & Schwarz on October 21, 2026. This pre-market activity occurred ahead of the company's scheduled third-quarter results release before the U.S. market opened, with analysts reportedly focusing on bioprocessing recovery and the new CEO's first earnings call. The stock's pre-market indication was given before the 9:00 a.m. CEST Xetra open.
Danaher (DHR) Tops Q3 EPS by 19c, Beats on Revenue; Offers FY26 EPS Guidance
Danaher (DHR) reported strong third-quarter results, surpassing analyst estimates with an EPS of $2.11, $0.19 higher than predicted, and revenue of $6.6 billion, exceeding the consensus of $6.56 billion. The company also provided optimistic guidance for fiscal year 2026, forecasting an EPS range of $8.57-$8.62, which is above the analyst consensus of $8.51.
Danaher: Q3 Earnings Snapshot
Danaher Corp. (DHR) reported strong third-quarter earnings, exceeding Wall Street expectations with adjusted profits of $2.11 per share. The company posted $1.24 billion in earnings and revenue of $6.55 billion, matching Street forecasts. Danaher also provided a full-year earnings outlook between $8.57 and $8.62 per share.
Vontier (VNT) Unveils Vantage Point As Undervalued Narrative Stays In Focus
Vontier (VNT) has launched its Vantage Point mobility intelligence platform, consolidating over 250 billion data points from various operations. This release coincides with Vontier's improving short-term stock momentum, despite longer-term declines. Simply Wall St's analysis suggests Vontier is 9% undervalued with a fair value of $37.42, though potential risks like sluggish core revenue growth and M&A strategies need consideration.
Danaher: Q3 Earnings Snapshot
Danaher Corp. (DHR) reported third-quarter earnings of $1.24 billion, or $1.75 per share, with adjusted earnings of $2.11 per share. These results surpassed Wall Street expectations, which had an average estimate of $1.92 per share. The company's revenue of $6.55 billion matched Street forecasts, and Danaher projects full-year earnings between $8.57 and $8.62 per share.
9 Health Care Stocks Whale Activity In Today’s Session
This article highlights significant options trading activity, often referred to as "whale activity," involving nine healthcare stocks: Fortrea Holdings (FTRE), Exelixis (EXEL), Danaher Corp (DHR), ImmunityBio Inc (IBRX), The Cigna Group (CI), Edwards Lifesciences Corp (EW), Thermo Fisher Scientific Inc (TMO), Intuitive Surgical Inc (ISRG), and Eli Lilly and Co (LLY). The analysis details specific call and put option trades, their sentiment (bullish, bearish, or neutral), expiration dates, strike prices, and total trade values, indicating potential future price movements for these companies. The information is derived from Benzinga's options activity scanner, which tracks large-sum transactions.
Danaher stock: At 7.19 percent below its 52-week high, Danaher stock sits at USD 225.35
Danaher Corporation's stock is currently trading at USD 225.35, which is 7.19 percent below its 52-week high of USD 242.80. The company reported an 8.00 percent year-over-year increase in adjusted earnings per share for the second quarter of 2026. Investors are anticipating the release of third-quarter 2026 earnings on October 21, 2026, for further assessment of the stock's performance.
Waters Launches AI Link to Advance AI-Enabled LC-MS Workflows
Waters Corporation has introduced Waters AI Link, a software capability that integrates Anthropic's Model Context Protocol into its waters_connect informatics platform, to enhance AI-enabled laboratory workflows. The company also joined Anthropic's Model Hardware Standard (MHS) research program to simplify the integration of AI agents with physical lab equipment. This initiative aims to streamline processes from research to regulated quality control, potentially accelerating development timelines and increasing demand for instruments and consumables.
Waters Launches AI Link to Advance AI-Enabled LC-MS Workflows
Waters Corporation has launched Waters AI Link, integrating Anthropic's Model Context Protocol into its waters_connect informatics platform to advance AI-enabled LC-MS workflows. The company also joined Anthropic's Model Hardware Standard (MHS) research program to standardize communication between AI agents and laboratory hardware. This initiative aims to streamline analytical method creation, data acquisition, and processing, extending AI-enhanced workflows from research to regulated quality-control environments, potentially compressing development timelines.
Danaher schedules third-quarter results: Danaher stock is valued at USD 157.8 billion
Danaher is scheduled to report its third-quarter results on October 21, 2026. The company is valued at USD 157.8 billion and its stock was trading at EUR 201.95. Investors are keen to see if its recovery in life sciences and diagnostics is expanding and how growth validates the improved full-year earnings range.
Danaher Corp. stock: results due October 21, 2026 pre-market
Danaher Corp. is scheduled to release its third-quarter results on October 21, 2026, before the opening bell. The company, which develops tools and services in biotechnology, diagnostics, and life sciences, was trading pre-market at EUR 199.20 on October 20, 2026, at Lang & Schwarz. Analyst expectations for the upcoming release were also mentioned in the report.
Danaher (DHR) Reports Q3: Everything You Need To Know Ahead Of Earnings
Danaher (DHR) is set to announce its Q3 earnings this Wednesday, with analysts expecting an 8.4% year-on-year revenue growth, an improvement from last year's 4.4% increase. The company has a history of beating Wall Street's revenue estimates, and analysts have largely reconfirmed their projections. Investors in the life sciences tools & services sector have seen stable share prices, with Danaher's stock up 3% in the last month.
Danaher Likely To Report Higher Q3 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earni
Danaher Corporation (NYSE: DHR) is expected to announce higher Q3 earnings on Wednesday, October 21st, with analysts forecasting $1.92 per share and $6.56 billion in revenue. Several highly-rated analysts have revised their price targets for DHR upward, following the company's recent AI collaboration with NVIDIA Corp.
Danaher Corp. stock pre-market at EUR 204.75: life sciences group
Danaher Corp. stock is trading pre-market at EUR 204.75 on October 19, 2026, at Lang & Schwarz. The company specializes in biotechnology, diagnostics, and life sciences tools and services. The pre-market indication is being monitored ahead of the Xetra open, with the S&P 500 serving as the benchmark for its U.S. home market.
Lincoln Electric Holdings, Inc. (LECO) Stock Forecasts
Argus has lowered its target price for Lincoln Electric Holdings, Inc. (LECO) to $290.00. Lincoln Electric is a major manufacturer of welding, cutting, and brazing products, including arc-welding solutions and automation systems. The company's stock is currently priced at $259.19.
Danaher advances autonomous science with NVIDIA as Danaher Corp. stock trades at EUR 204.00
Danaher Corporation announced a collaboration with NVIDIA on October 14, 2026, to advance autonomous science by combining Danaher's scientific instrumentation and expertise with NVIDIA's accelerated computing and AI technologies. Danaher Corp. stock was trading at EUR 204.00 in weekend trading on October 18, 2026, with the next Xetra session scheduled for October 19, 2026. The company's third-quarter 2026 earnings call is set for October 21, 2026.
Danaher advances autonomous science with NVIDIA as Danaher Corp. stock trades at EUR 204.00
Danaher Corporation has announced a collaboration with NVIDIA to advance autonomous science, combining Danaher's scientific instrumentation and AI technologies. This news comes as Danaher Corp. stock was trading at EUR 204.00 in weekend trading. Initial efforts will focus on select instruments, with potential for broader expansion.
JPMorgan cuts Fortive stock target to USD 56.00, 3.10 percent below price
JPMorgan has lowered its price target for Fortive Corp. (FTV) to USD 56.00 from USD 64.00, maintaining an underweight rating, which is 3.10 percent below the last NYSE closing price of USD 57.79. The company's next third-quarter earnings call is scheduled for October 28, 2026, which will serve as the next significant update for investors. Fortive's stock currently trades within its 52-week range, with a market capitalization of USD 17.5 billion and a P/E ratio of 33.99, higher than some of its peers.
QuidelOrtho stock closed at USD 12.91 on October 16, down 7.19 percent
QuidelOrtho stock (QDEL) closed at USD 12.91 on October 16, 2026, down 7.19 percent on Nasdaq. The company reported second-quarter 2026 revenue of USD 630.90 million and a GAAP net loss of USD 92.90 million. Investors are looking forward to the next estimated earnings date on November 5, 2026, for further financial clarity and a full-year outlook.
Bio-Techne stock has a November 4, 2026 reporting date
Bio-Techne (ISIN US09073M1045) is scheduled to release its next quarterly report on November 4, 2026, with an estimated revenue of USD 292.61 million for the upcoming quarter. The stock's last recorded price was EUR 64.57 on October 16, 2026, and its P/E ratio stands at 62.56. Investors will compare the upcoming figures against the fiscal year 2026 results, which showed USD 321.2 million in revenue and an adjusted gross margin of 69.2 percent.
Beckman Coulter Diagnostics Names New President
Beckman Coulter Diagnostics has appointed Catherine "Cat" Jennings as its new president. Jennings, who previously oversaw a $2 billion global division at Boston Scientific, brings over two decades of healthcare industry leadership experience. In her new role, she will be responsible for leading the company’s strategic, operational, and organizational operations, focusing on accelerating innovation and expanding the impact of diagnostic solutions worldwide.
A director reports 46,915 trust-held shares in Danaher (DHR), plus employee stock options.
Danaher Corporation director Daniel L. Comas reported his holdings, which include 18,804 common shares held by a trust, 46,915 shares by a Grantor Retained Annuity Trust, 2,543 by his spouse, and 6 through a 401K. Additionally, his account lists 52,338 notional shares in Danaher’s deferred compensation stock fund and employee options covering a total of 85,254 common shares with various exercise prices and expiration dates. This report provides a detailed overview of his beneficial ownership in DHR, as filed in a Form 3.
Danaher adds two directors before third-quarter results
Danaher Corporation announced the appointment of two new directors, Daniel L. Comas and Robert Hershberg, on October 9, 2026, expanding its board to 13 members. This announcement comes shortly before the company is scheduled to release its third-quarter 2026 results on October 21, 2026. Additionally, Alan G. Spoon will not seek re-election at the 2027 Annual Meeting of Shareholders.
Illinois Tool Works Inc. (ITW) Stock Forecasts
This article provides an analyst report from Morningstar on Illinois Tool Works Inc. (ITW), highlighting its strong organic growth and wide-moat portfolio. Founded in 1912, ITW is a diversified industrial manufacturer operating through seven business segments. The report also lists other related analyst reports for companies like Danaher Corporation, Caterpillar Inc., and Rockwell Automation, Inc.
